- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT01795027
Compare S-1 Plus Oxaliplatin to S-1 as Adjuvant Chemotherapy After D2 Resection in Patients With Gastric Cancer (CAPITAL)
A Prospective,Multicentral,Open-label,Randomized,Controlled,Phase III Clinical Trial to Compare S-1 Plus Oxaliplatin to S-1 as Adjuvant Chemotherapy After D2 Resection in Patients With Gastric Cancer
Background: It is shown that TS-1 as adjuvant chemotherapy after D2 resection in patients with gastric cancer can improve DFS and OS in one Japanese Trial. And TS-1 has become one of the standard therapies to these patients. But it is still unknown whether it would improve more to OS and DFS than single TS-1 after combined with oxaliplatin . This trial is designed to investigate the efficacy and safety of TS-1 plus oxaliplatin versus TS-1 single as adjuvant chemotherapy after D2 resection in patients with gastric cancer.
Patients and methods: In this study , patients with histologically confirmed gastric cancer who received D2 resection and staged II or III, aged from 18 to 70 years and with Eastern Cooperative Oncology Group performance status ≤2 and adequate organ function, are randomized 1:1 to oxaliplatin 100mg/m2 on day 1 and TS-1 40~60mg twice everyday for 14 days in a 21-days cycle for total 6 cycles followed by TS-1 single with the same dose and frequency to the end of the 1st year postoperatively(SOX) , or TS-1 single 40~60mg twice everyday for 14 days in a 21-days cycle to the end of the 1st year postoperatively (TS-1). The primary end point is overall survival (OS), and secondary end point is disease free survival(DFS) and safety. Final study analysis will be conducted in the end of the 5th year after the last patient's enrollment.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Förväntat)
Fas
- Fas 3
Kontakter och platser
Studieorter
-
-
Guangdong
-
Chaozhou, Guangdong, Kina
- the central hospital of Chaozhou
-
Foshan, Guangdong, Kina
- The 1st People's Hospital of Foshan
-
Guangzhou, Guangdong, Kina
- Cancer center of Sun Yat-sen University
-
Guangzhou, Guangdong, Kina
- cancer center of Guangzhou medical college
-
Guangzhou, Guangdong, Kina
- Guangdong Traditional Medical Hospital
-
Guangzhou, Guangdong, Kina
- the 1st affliated hospital of Guangdong pharmacuetic college
-
Guangzhou, Guangdong, Kina
- the 1St Affliated Hospital of Guangzhou Medical College
-
Guangzhou, Guangdong, Kina
- the 6th affliated hospital of Sun-yat-sen University
-
Shantou, Guangdong, Kina
- the 1st hospital of Shantou University
-
Shantou, Guangdong, Kina
- the cental hospital of Shantou
-
Shaoguan, Guangdong, Kina
- YUE-BEI people's hospital
-
Shenzhen, Guangdong, Kina
- The 2nd People's Hospital of Shenzhen
-
Zhuhai, Guangdong, Kina
- the 5th hospital of Sun-yat-sen University
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- informed consensus of patients
- be able to receive oral administration
- from 18 to 70 years old
- be proven to be primary adenocarcinoma of gastric cancer and staged II or III by pathological evidences
- without other chemotherapy and/or radiation against to the disease
- normal function of other organs including heart,liver ,kidney and so on
- Eastern Cooperative Oncology Group performance status:0~2
Exclusion Criteria:
- history of other malignancy
- allergic reaction to S-1 or oxaliplatin
- be enrolling in other clinical trials
- abnormal GI tract function
- dysfunction of other organs
- female in pregnancy or lactation,or refuse to receive Contraception measures during chemotherapy
- other situation to be judged not adaptive to the study by investigators
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Experimentell: S-1 plus Oxaliplatin
6 courses chemotherapy with S-1 plus oxaliplatin followed by 10 courses S-1 single after d D2 resection
|
6 courses chemotherapy with S-1 plus oxaliplatin followed by 10 courses S-1 single after d D2 resection
Andra namn:
|
Aktiv komparator: S-1 single
S-1 40~60mg twice daily for 14 days in 3 weeks for totally 16 courses after D2 resection
|
16 courses S-1 single after d D2 resection
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
---|---|
total överlevnad
Tidsram: 5 år
|
5 år
|
Sekundära resultatmått
Resultatmått |
Tidsram |
---|---|
sjukdomsfri överlevnad
Tidsram: 3 år
|
3 år
|
Antal deltagare med negativa händelser
Tidsram: 5 år
|
5 år
|
Samarbetspartners och utredare
Sponsor
Utredare
- Studiestol: Zhiwei Zhou, PHD, SunYat-sen University
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Förväntat)
Avslutad studie (Förväntat)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- SYSUCCGPS
- ZHOUZHIWEI (Registeridentifierare: ZZHIWEI)
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Magcancer
-
Universitätsklinikum Hamburg-EppendorfCentre Hospitalier Universitaire de Nice; Olympus Corporation; Keio University och andra samarbetspartnersAvslutadGastric Focal LesionFrankrike
-
Washington University School of MedicineNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)AvslutadRoux-en-Y Gastric Bypass | Bariatrisk kirurgi | Vertikal sleeve gastrectomy | Magbandning | Bypass, GastricFörenta staterna
-
RSP Systems A/SAvslutad
-
State University of New York - Upstate Medical...AvslutadGastric Bypass StatusFörenta staterna
-
Mayo ClinicNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)IndragenGastric Bypass-kirurgi
-
Medtronic - MITGAvslutad
-
Wageningen UniversityRijnstate HospitalOkändRoux-en-Y Gastric BypassNederländerna
-
North Dakota State UniversityNeuropsychiatric Research Institute, Fargo, North DakotaAvslutadRoux en Y Gastric BypassFörenta staterna
-
DuomedAktiv, inte rekryterandeFetma | Gastrektomi | Roux-en-Y Gastric Bypass | Mini Gastric BypassBelgien
-
Olympus Corporation of the AmericasUnity Health TorontoAvslutad
Kliniska prövningar på S-1 plus oxaliplatin
-
Xijing HospitalOkänd
-
Peking University Cancer Hospital & InstituteRekrytering
-
Yonsei UniversityAvslutadAvancerad magcancerKorea, Republiken av
-
Taiho Pharmaceutical Co., Ltd.Yakult Honsha Co., LTDAvslutadMagcancerJapan, Korea, Republiken av
-
Lin ChenOkändGastriskt adenokarcinomKina
-
Zhejiang UniversityRekryteringLokalt avancerad gastriskt karcinomKina
-
AIPING ZHOUHar inte rekryterat ännuImmunterapi | Sintilimab | Lokalt avancerad solid tumör | Oxaliplatin | HER2-positiv | Gastriskt eller Gastroesofageal Junction Adenocarcinoma | S-1Kina
-
Sixth Affiliated Hospital, Sun Yat-sen UniversitySun Yat-sen UniversityRekryteringKemoterapi effekt | Lokalt avancerad gastroesofageal junction AdenocarcinomaKina
-
Huazhong University of Science and TechnologyCSPC Ouyi Pharmaceutical Co., Ltd.Rekrytering
-
First Affiliated Hospital, Sun Yat-Sen UniversityAvslutadMagcancer | Kirurgi | Komplettera komponentbristKina